Romiplostim Drug Aliquot | Anti-TPOreceptor | Therapeutic Peptibody

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Romiplostim are now available as research consumables.

Romiplostim drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Romiplostim drug can be ordered at the same time. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Nplate Romiplostim Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

NPlate® / Romiplostim Reference Product

Drug nameNplate®
INNromiplostim
API typeFc-peptide fusion protein (peptibody)
Pharmacotherapeutic group
Antihaemorrhagics, other systemic haemostatics
ATC code
B02BX04
Target of antibody
TPO receptor (also known as cMpl)
General functionNplate is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Nplate is indicated for the treatment of chronic primary immune thrombocytopenia (ITP) in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Romiplostim is an Fc-peptide fusion protein (peptibody) that signals and activates intracellular transcriptional pathways via the TPO receptor (also known as cMpl) to increase platelet production. The peptibody molecule is comprised of a human immunoglobulin IgG1 Fc domain, with each single-chain subunit covalently linked at the C-terminus to a peptide chain containing 2 TPO receptor-binding domains. Romiplostim has no amino acid sequence homology to endogenous TPO. In pre-clinical and clinical trials no anti-romiplostim antibodies cross reacted with endogenous TPO.

The pharmacokinetics of romiplostim involved target-mediated disposition, which is presumably mediated by TPO receptors on platelets and other cells of the thrombopoietic lineage such as megakaryocytes.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)The pharmacokinetics of romiplostim involved target-mediated disposition, which is presumably mediated by TPO receptors on platelets and other cells of the thrombopoietic lineage such as megakaryocytes.

Due to the formation of neutralising antibodies pharmacodynamic effects of romiplostim in rats were often decreasing at prolonged duration of administration. Toxicokinetic studies showed no interaction of the antibodies with the measured concentrations.
Original license holder
Amgen Europe B.V.
Marketing authorisation numbers
EU/1/08/497/005 EU/1/08/497/006 EU/1/08/497/007 EU/1/08/497/008
Marketing authorisation holder
Amgen Europe B.V. Minervum 7061 4817 ZK Breda The Netherlands
Name of the manufacturer of the biological active substance
Amgen Inc One Amgen Center Drive Thousand Oaks, CA 91320 USA
Name and address of the manufacturer(s) responsible for batch releaseAmgen Europe B.V. Minervum 7061 NL-4817 ZK Breda The Netherlands
Max shelf life
3 years
Storage conditions
2°C – 8°C
List of excipients
Mannitol (E421), Sucrose, L-histidine, Hydrochloric acid (for pH adjustment), Polysorbate 20

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.